Physician profile
Xiaobin Li
NPI 1346225034
$5,715.62
in general payments reported to CMS, 2019-2025
37 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,827 · 2020: $270 · 2021: $658 · 2022: $702 · 2023: $1,250 · 2024: $555 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,258.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,040.60 | 2019-2025 | |
| Lilly USA, LLC | $847.04 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Gilead Sciences, INC. | $761.21 | 2019-2025 | Vemlidy |
| Glaxosmithkline, LLC. | $501.01 | 2019-2024 | Shingrix, Trelegy Ellipta, Bexsero |
| Merck Sharp & Dohme LLC | $329.73 | 2019-2023 | Belsomra, Steglatro |
| Amgen INC. | $224.33 | 2019-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.31 | 2019-2024 | Jardiance, Tradjenta |
| Allergan, INC. | $171.89 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $136.94 | 2023 | Quviviq |
| Redhill Biopharma INC. | $119.83 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $119.71 | 2019-2025 | |
| Novo Nordisk INC | $112.04 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.26 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $98.76 | 2019-2022 | |
| Abbott Laboratories | $89.51 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $82.54 | 2021-2022 | |
| Medtronic USA, INC. | $80.00 | 2019 | |
| Genentech USA, INC. | $55.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $52.31 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $50.00 | 2021 | |
| Amarin Pharma, INC. | $49.26 | 2019-2023 | |
| Vivus LLC | $43.07 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $42.66 | 2022 | |
| Phadia US INC. | $35.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.83 | 2022-2023 | |
| Evoke Pharma, INC. | $34.31 | 2022-2025 | |
| Pfizer INC. | $31.89 | 2019-2023 | |
| Seqirus USA INC | $30.84 | 2019 | |
| Phathom Pharmaceuticals, INC. | $29.46 | 2025 | Voquezna |
| Ani Pharmaceuticals, INC. | $26.10 | 2024 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $25.49 | 2023 | Lupkynis |
| Exact Sciences Corporation | $25.21 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $25.06 | 2019-2020 | |
| Lupin INC. | $24.84 | 2019 | |
| Medtronic, INC. | $24.03 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.73 | 2022 | |
| Romark Laboratories, Lc | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaobin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.